Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Country Of Origin Labeling Could Confuse Consumers, Increase OTC Costs

This article was originally published in The Tan Sheet

Executive Summary

Country-of-origin labeling for drugs could drive OTC manufacturing costs up and confuse consumers with unnecessary information on labels, industry stakeholders say
Advertisement

Related Content

Threat Of Adulteration For Profit Grows With Globalization Of Supply Chain
Threat Of Adulteration For Profit Grows With Globalization Of Supply Chain
Country-Of-Origin Labeling Would Add Costs But No Consumer Benefit – CRN
Drug Manufacturers’ Supply Options Could Be Constricted By Legislation
FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push
FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push
Advertisement
UsernamePublicRestriction

Register

PS102163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel